secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274235
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366
--------------------------------------------------------------------------------

- Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.
- Cash, cash equivalents and marketable securities $232.6M as of Sep 30, 2025; projected to fund operations into late 2027.
- Raised $175M gross proceeds from equity financing with institutional investors in August 2025.
- Positive Phase 1b interim data for ABI-5366: significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.
- Phase 1a interim data for ABI-6250 supports progression to Phase 2; additional HSV data (ABI-5366, ABI-1179) expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/0001193125-25-274235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/asmb-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer